SCHEMBL4926286

SCHEMBL4926286

COc1cc2nc(N)c(Cl)nc2cc1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGK1 P00558 5/20 0.58
NQO2 P16083 1/20 0.48
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.47
GAA P10253 3/20 0.47
GLA P06280 2/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
TLR8 Q9NR97 1/20 0.46
KMT2A Q03164 3/20 0.44
LMNA P02545 2/20 0.44
POLB P06746 1/20 0.44
SMARCA2 P51531 1/20 0.44
ACHE P22303 1/20 0.41
GSK3B P49841 1/20 0.41
MAP4K2 Q12851 1/20 0.41
NQO1 P15559 1/20 0.41
MEN1 O00255 2/20 0.41
PDPK1 O15530 1/20 0.40
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31530749 0.85 PGK1 (0.68) PGK1NQO2KDM4EALDH1A1GAA
SCHEMBL1291729 0.85 PGK1 (0.68) PGK1NQO2KDM4EALDH1A1GAA
SCHEMBL1138242 0.78 ALDH1A1 (0.58) NQO2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL4928310 0.78 NQO2 (0.50) PGK1NQO2KDM4EALDH1A1GAA
SCHEMBL121613 0.77 CYP3A4 (0.48) PGK1NQO2KDM4EALDH1A1GAA
SCHEMBL4921900 0.76 GLP1R (0.52) PGK1NQO2KDM4EALDH1A1GAA
SCHEMBL21642300 0.76 PGK1 (0.72) PGK1NQO2KDM4EALDH1A1SMN1; SMN2
SCHEMBL1291803 0.75 PGK1 (0.65) PGK1NQO2KDM4EALDH1A1GAA
SCHEMBL21642543 0.73 PGK1 (0.55) PGK1NQO2KDM4EALDH1A1SMN1; SMN2
SCHEMBL1291876 0.73 PGK1 (1.00) PGK1NQO2KDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598173-B2 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives for treating tumors KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2013-12-03 US disclosed
US-20130053390-A1 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES REXAHN PHARMACEUTICALS, INC. 2013-02-28 US disclosed
US-8314100-B2 1-[6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives REXAHN PHARMACEUTICALS, INC. (US) 2012-11-20 US disclosed
US-20080318963-A1 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives REXAHN PHARMACEUTICALS, INC. (US) 2008-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318963-A1 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives HRAS, CDK4, KRAS PGK1 438/4885NQO2 56/4885KDM4E 502/4885
US-20130053390-A1 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES HRAS, CDK4, KRAS PGK1 594/4885NQO2 51/4885KDM4E 843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.